150349-65-8

Basic information

• Product Name: TERT-BUTYL 4-(3-AMINOPROPYL)PIPERIDINE-1-CARBOXYLATE
• Synonyms: TERT-BUTYL 4-(3-AMINOPROPYL)PIPERIDINE-1-CARBOXYLATE;1-Boc-4-(3-aminopropyl)piperidine;4-(3-Aminopropyl)piperidine-1-carboxylic acid tert-butyl ester;tert-Butyl 4-(3-aminopropyl)
• CAS NO: 150349-65-8
• Molecular Formula: C₁₃H₂₆N₂O₂
• Molecular Weight: 242.36
• Mol File: 150349-65-8.mol

Chemical Properties

• Boiling Point: 332.1°C at 760 mmHg
• Flash Point: 154.7°C
• Appearance: /
• Density: 0.999g/cm³
• Vapor Pressure: 0.000149mmHg at 25°C
• Refractive Index: 1.48
• PKA: 10.55±0.10(Predicted)
• CAS DataBase Reference: TERT-BUTYL 4-(3-AMINOPROPYL)PIPERIDINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-(3-AMINOPROPYL)PIPERIDINE-1-CARBOXYLATE(150349-65-8)
• EPA Substance Registry System: TERT-BUTYL 4-(3-AMINOPROPYL)PIPERIDINE-1-CARBOXYLATE(150349-65-8)

Safety Data

• Hazardous Substances Data: 150349-65-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 4-(3-AMINOPROPYL)PIPERIDINE-1-CARBOXYLATE is used as a key intermediate in the synthesis of various pharmaceutical drugs. Its unique chemical structure allows it to be a valuable component in the development of new medications, enhancing their efficacy and safety.
Used as a Chemical Reagent:
In addition to its pharmaceutical applications, TERT-BUTYL 4-(3-AMINOPROPYL)PIPERIDINE-1-CARBOXYLATE is utilized as a chemical reagent. Its reactivity and stability make it suitable for use in various chemical reactions, facilitating the production of other compounds and materials.
Used in Organic Synthesis Processes:
TERT-BUTYL 4-(3-AMINOPROPYL)PIPERIDINE-1-CARBOXYLATE also finds application in organic synthesis processes. Its presence can influence the outcome of these reactions, leading to the creation of new organic compounds with potential uses in various industries.
Safety and Handling:
It is crucial to handle and store TERT-BUTYL 4-(3-AMINOPROPYL)PIPERIDINE-1-CARBOXYLATE according to safe laboratory practices. Adherence to applicable regulations and guidelines ensures the safety of personnel and the environment during its use in research and industrial applications.

InChI:InChI=1/C13H26N2O2/c1-13(2,3)17-12(16)15-9-6-11(7-10-15)5-4-8-14/h11H,4-10,14H2,1-3H3

Upstream product

• 161975-20-8 tert-butyl 4-(2-cyanoethyl)piperidine-1-carboxylate 
• 2629-72-3 4-(3-Hydroxypropyl)pyridine 
• 156185-63-6 N-Boc-piperidin-4-yl-propanol 
• 7037-49-2 3-(piperidin-4-yl)propan-1-ol 
• 946517-74-4 4-(3-azido-propyl)-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 307301-62-8 N-[2-[1-(tert-butoxycarbonyl)piperidin-4-yl]propyl]-7-(4-methylphenyl)-2,3-dihydro-1-benzooxepine-4-carboxamide 
• 203867-81-6 4,5-dihydro-4-[3-(1-tert-butoxycarbonylpiperidin-4-yl)propan-1-yl]-3H-1,4,8b-triazaacenaphthylen-3-one 
• 1021361-57-8 4-[2-(4-bromo-2-chlorophenoxy)phenylsulfamoyl]-N-(3-piperidin-4-ylpropyl)benzamide hydrochloride 

Relevant articles and documents

Guided rational design with scaffold hopping leading to novel histamine H3 receptor ligands

During the past decades, histamine H3 receptors have received widespread attention in pharmaceutical research due to their involvement in pathophysiology of several diseases such as neurodegenerative disorders. In this context, blocking of thes

N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE

Provided herein are certain substituted N-aryl and N-heteroaryl piperidine compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, L, R4, L1, Q, R5 and R 6 are as defined. The said novel compounds, and pharmaceutically acceptable compositions comprising a compound thereof, may be useful as Liver X-β receptor(LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory disease and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS

The present invention relates to new sulfonamide derivatives of formula (I), wherein R1-R8 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective antagonists of bradykinin B1, to processes for producing these same compounds, pharmacological compositions containing them and to their use in therapy or prevention of painful and inflammatory conditions.

NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS

The present invention relates to new sulfonamide derivatives of formula (I), wherein R1 -R5 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective antagonists of bradykinin B1, to processes for producing these compounds, pharmacological compositions containing them and to their use in therapy or prevention of painful and inflammatory conditions.

[4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases

The present invention provides compounds of Formula I: useful in the treatment of cancer and inflammatory diseases.

Fused imidazopyridine derivatives as antihyperlipidemic agents

A novel compound of the formula: wherein ring Q is an optionally substituted pyridine ring; One of R0, R1and R2is —Y0—Z0, and the other tow groups are a hydrogen, a halogen, an optionally substituted hydroxy group, a hydrocarbon group that may be an optionally substituted hydrocarbon group or an acyl group; Y0is a bond or an optionally substituted bivalent hydrocarbon group; Z0is a basic group which may be bonded via oxygen, nitrogen, —CO—, —CS—, —SO2N(R3)— (where R3is hydrogen or an optionally substituted hydrocarbon group), or S(O)n(wherein n is to 0, 1 or 2); .........is a single bond or a double bond, or a salt thereof, which has an excellent LDL receptor up-regulating, blood-lipids lowering, blood-sugar lowering and diabetic complication-ameliorating activity.

Fibrinogen receptor antagonists

Fibrinogen receptor antagonists having the formula STR1 for example STR2